Lamicon 1% cream, 15 g per tube
Ingredients
Active ingredient: terbinafine;
1 g of cream contains 0.01 g of terbinafine hydrochloride, calculated as 100% anhydrous substance;
excipients: phenylethyl alcohol, white soft paraffin, mineral oil, cetostearyl alcohol, polyethylene glycol (macrogol) 20 cetostearyl ether, propylene glycol, poloxamer 407, sodium hydroxide, purified water.
Dosage Form
Cream.
Main physical and chemical properties: a white or nearly white cream with a characteristic odor.
Pharmacotherapeutic group
Antifungal agents for topical use.
ATC code D01A E15.
Pharmacological properties
Pharmacodynamics.
Terbinafine is an allylamine and has a broad spectrum of antifungal activity. At low concentrations, terbinafine exerts a fungicidal effect against dermatophytes, molds, and certain dimorphic fungi. Activity against yeasts, depending on the species, may be fungicidal or fungistatic. The drug has a prolonged effect, allowing the desired outcome to be achieved within a short treatment period.
Terbinafine specifically inhibits the early stage of sterol biosynthesis in the fungal cell membrane. This leads to a deficiency of ergosterol and intracellular accumulation of squalene, resulting in the death of the fungal cell. Terbinafine acts by inhibiting the enzyme squalene epoxidase in the fungal cell membrane. This enzyme is not part of the cytochrome P450 system. Terbinafine does not affect the metabolism of hormonal agents or other medications.
Pharmacokinetics.
When applied topically, less than 5% of the dose is absorbed; therefore, the absorption of terbinafine into the systemic circulation is negligible.
Terbinafine begins to act rapidly and is effective with short-term treatment (7 days). After 7 days of treatment with Lamicon® cream, concentrations of terbinafine exceeding those required for fungicidal activity remain in the stratum corneum for at least 7 days after discontinuation of treatment.
Indications
Fungal skin infections caused by dermatophytes such as Trichophyton (e.g., T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis, and Epidermophyton floccosum, such as tinea pedis; tinea cruris (“jock itch”); tinea corporis (“ringworm of the body”); cutaneous candidiasis caused by fungi of the genus Candida, usually Candida albicans; pityriasis versicolor, caused by Pityrosporum orbiculare (also known as Malassezia furfur).
Contraindications
Hypersensitivity to terbinafine or to any of the drug’s components.
Drug Interactions and Other Interactions
None known.
Special Instructions for Use
The cream is intended for external use only. Avoid contact with the eyes, as the medication may cause irritation. If the cream accidentally gets into the eyes, rinse them thoroughly with running water. Lamikon®, cream, contains cetostearyl alcohol, which may cause local skin irritation (e.g., contact dermatitis).
Lamicon® cream contains propylene glycol, which may cause skin irritation.
To prevent reinfection with skin fungal infections, follow these guidelines: change your underwear daily, as fungi may be present on clothing that has come into contact with infected skin areas; avoid wearing clothing that is too tight or does not allow air to circulate properly; thoroughly dry affected areas of the skin after washing; use a clean, personal towel every day. If you have a fungal infection of the feet, do not walk barefoot. In addition to topical treatment, it is recommended to spray the inside of your socks or shoes with Lamicon® once a day.
In animal studies, no effect of terbinafine on fertility was observed.
Use during pregnancy or breastfeeding.
Animal studies have not shown any embryotoxic effects of terbinafine. Since clinical experience with the use of this medication in pregnant women is limited, Lamicon® cream should not be used by pregnant women, except in cases where, in the physician’s opinion, the expected benefit to the mother outweighs the potential risk to the fetus.
Terbinafine passes into breast milk; therefore, the drug should not be used by women who are breastfeeding. Infants should avoid contact with skin where the cream has been applied, including the breasts.
Effect on the ability to drive or operate machinery.
No effect.
Directions for Use and Dosage
The cream is intended for external use only.
For adults and children 12 years of age and older.
Apply Lamikon® cream to the skin 1 or 2 times a day, depending on the condition. Before applying the cream, thoroughly clean and dry the affected areas. Apply a thin layer of the cream to the affected skin and surrounding areas, rubbing it in gently. For infections accompanied by intertrigo (under the breasts, between the toes, in the groin area, and between the buttocks), the application sites may be covered with gauze, especially at night.
Duration and frequency of treatment.
The duration of treatment depends on the severity of the condition:
- interdigital dermatophytosis of the feet, inguinal dermatophytosis, and dermatophytosis of the trunk: once daily for 1 week;
- squamous-hyperkeratotic tinea pedis (“moccasin foot”): twice daily for 2 weeks;
- cutaneous candidiasis: 1–2 times daily for 1 week;
- tinea versicolor: 1–2 times daily for 2 weeks.
No dose adjustment is necessary for elderly patients.
Symptoms usually improve within a few days. Irregular use or premature discontinuation of treatment may lead to a relapse.
If there are no signs of improvement after 2 weeks of treatment, consult a doctor.
Children.
Experience with the use of this medication in children under 12 years of age is limited; therefore, the medication should not be used in this age group.
Overdose
The low systemic absorption of terbinafine following topical application makes an overdose extremely unlikely. Accidental ingestion of the contents of two 30-g tubes (containing 300 mg of terbinafine hydrochloride) is comparable to taking 1 Lamicon® tablet 250 mg tablets (oral dosage form). In the event of an overdose caused by accidental ingestion of a large amount of cream, side effects are expected to be similar to those seen with an overdose of Lamicon® tablets (headache, nausea, epigastric pain, and dizziness).
Treatment of an overdose following accidental ingestion involves removing the active ingredient, primarily by administering activated charcoal, and providing symptomatic therapy as needed.
Side Effects
Local reactions, such as itching, peeling, or a burning sensation of the skin, pain and irritation at the application site, pigmentation changes, erythema, and crusting, may occur at the application site. These minor reactions should be distinguished from hypersensitivity reactions, including rashes, which have been reported in isolated cases and require discontinuation of treatment. If terbinafine hydrochloride accidentally comes into contact with the eyes, it may cause eye irritation. In rare cases, a latent fungal infection may flare up.
Possible side effects:
Immune system
Frequency unknown (cannot be estimated from available data): hypersensitivity reactions, including urticaria*. In isolated cases—angioedema and anaphylactic shock.
Eye disorders
Rare (≥ 1/10,000, < 1/1,000): eye irritation.
Skin and connective tissue disorders
Common (≥ 1/100, < 1/10): skin peeling, itching.
Uncommon (≥ 1/1,000, < 1/100): skin damage, crusting, skin lesions, pigmentation disorders, erythema, burning sensation of the skin.
Rare (≥ 1/10,000, < 1/1,000): dry skin, contact dermatitis (including bullous dermatitis), eczema.
Frequency unknown (cannot be estimated from the available data): rash* or blistering.
General disorders and administration site conditions
Uncommon (≥ 1/1,000, < 1/100): pain, pain at the application site, irritation at the application site.
Rare (≥ 1/10,000, < 1/1,000): exacerbation of symptoms.
* Data obtained from postmarketing surveillance.
Shelf life
3 years.
Do not use this medication after the expiration date printed on the package.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze the product. Keep out of the reach of children.
Packaging
15 g per tube. 1 tube per pack.
Dispensing Category
Over-the-counter.
Manufacturer
JSC “Farmak.”
Similar products
Products from the same category












